Multi-mode ferroptosis inducing molecule as well as preparation method and application thereof

By preparing the multimodal ferrody death-induced molecule Fc-ss-SN38, it regulates the metabolism of iron ions, amino acids and glutathione in tumor cells, solving the problem of colorectal cancer's inherent resistance to ferrody death, significantly improving the treatment effect, and achieving Multimodal enhancement of ferrodysfunction strategies is provided by the known drug SN38 to provide a pragmatic approach for clinical application.

CN118994263AActive Publication Date: 2024-11-22ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411179993.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-22
Estimated Expiration
2044-08-27

AI Technical Summary

Technical Problem

In the prior art, when using the ferrodynamic strategy to treat colorectal cancer, the intrinsic resistance of tumor cells to ferrodynamic death leads to poor treatment effect, and it is difficult to maximize the therapeutic effect by integrating the ferrodynamic pathway by a single or dual method.

Method used

Prepare a multimodal ferrodemortem inducing molecule Fc-ss-SN38, which regulates iron ions, amino acids and glutamic acids in tumor cells by chemical coupling of SN38 with ferrocene through bis(2-hydroxyethyl)disulfide ether Glyone metabolism enhances the ferrodynamic effect.

Benefits of technology

Significantly improve the ferrodysemia sensitivity of colorectal cancer cells, enhance the efficacy of chemotherapy, improve the therapeutic indicators through multi-modal strategies, and use the known safe clinical drug SN38 as a precursor to realize drug reuse, providing a clinical application Pragmatic method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994263A_ABST
    Figure CN118994263A_ABST
Patent Text Reader

Abstract

The invention provides a multi-mode ferroptosis inducing molecule as well as a preparation method and application thereof, relates to the technical field of drug development, and provides a method for preparing a ferrocene modified SN38 prodrug and exploring the self-assembly characteristic of the prepared prodrug and the potential of inducing ferroptosis to treat colorectal cancer. The ferrocene modified SN38 prodrug is prepared by chemically coupling SN38 and ferrocenedicarboxylic acid through esterification reaction of bis (2-ethoxyl) disulfide, and the prodrug has a GSH response characteristic, can realize specific response release of a tumor microenvironment, and can reduce toxic and side effects on normal tissues while improving a killing effect on tumor cells. The method for preparing the functionalized prodrug provided by the invention can be popularized to series compounds (paclitaxel, adriamycin, R848, all-transretinoic acid, salazosulfapyridine and the like) containing reaction sites of hydroxyl, amino and the like, and lays a foundation for optimizing clinical application of approved drugs and improving clinical application insufficiency of the drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical fields of biology, material science, synthesis of functionalized nanomaterials, regulation of assembly morphology, treatment of colorectal cancer, drug delivery, and the like, and specifically to a multimodal ferroptosis-inducing molecule and a preparation method and application thereof, and in particular to the preparation and application of the Fc-ss-SN38 multimodal ferroptosis-inducing molecule. Background Art

[0002] Colorectal cancer has rapidly developed into one of the major global health problems, and its etiology is closely related to the process of industrialization. Emerging research has positioned ferroptosis as a powerful anti-tumor modality, introducing a key avenue for colorectal cancer management. However, compared with normal colon tissue, glutathione peroxidase 4 (GPX4) is significantly upregulated in colorectal cancer tissue, and the intrinsic resistance of colorectal cancer to ferroptosis weakens its therapeutic effect. To solve this therapeutic deadlock, it is necessary to increase the sensitivity of colorectal cancer cells to ferroptosis. Studies have described four major sensitization strategies: (1) regulating iron ion metabolism to increase the iron ion content in tumor cells; (2) regulating ferroptosis-related lipid metabolism to promote the accumulation of unsaturated lipid peroxides; (3) manipulating amino acid metabolism; and (4) strictly controlling glutathione synthesis and degradation. The first two sensitization strategies discussed above enhance the lipid peroxide generation system, while the latter two strategies impair the lipid peroxide clearance system. In this context, the key to iron metabolism is to enhance the chelation of endogenous iron and the meticulous targeting of exogenous iron to tumor sites, thereby amplifying the efficacy of ferroptosis through local cellular iron overload. In addition, the regulation of ferroptosis-related lipid metabolism is mainly achieved through lipid peroxidation catalyzed by enzymes such as arachidonic acid 12-lipoxygenase (ALOX12). At the same time, the regulation of amino acid metabolism, mainly through the inhibition of glutaminase activity, limits the uptake of specific amino acids, especially cystine, thereby reducing the concentration of intracellular reduced glutathione (GSH) and weakening tumor resistance to ferroptosis. During lipid peroxidation, highly reactive lipid free radicals are produced, thereby enhancing ferroptosis. Despite these advances, cancer cells show a remarkable ability to activate compensatory mechanisms after amino acid inhibition, aiming to restore GSH synthesis through alternative biochemical pathways. Therefore, the increase in ferroptosis sensitivity has shifted to the regulation of GSH metabolism. This requires not only the consumption of excess reduced glutathione, but also the inhibition of the regeneration and conversion of oxidized glutathione (GSSG) to reduced glutathione, which together reduce glutathione reserves in tumor cells and amplify the ferroptosis response.

[0003] Ferroptosis is a multifactorial and synergistically regulated cell death mode, and the above-mentioned pathways interactively affect the ferroptosis of tumor cells. Integrating these pathways to enhance ferroptosis through single or dual approaches is insufficient in maximizing the therapeutic effect. Therefore, we propose a comprehensive multimodal strategy to enhance ferroptosis by simultaneously regulating the metabolism of iron ions, amino acids, and glutathione synthesis in tumor cells to significantly improve therapeutic indicators. A pragmatic approach to bring this strategy closer to clinical application is to use existing clinical drugs as the main reference for drug selection and combination therapy, that is, drug repurposing, that is, using mature drugs with known safety for new oncology uses. Drug repurposing has become an important and promising strategy in cancer treatment, providing important insights into strategic drug selection and synergistic combinations. However, the implementation of drug repurposing in tumor treatment to achieve clinically potential multimodal ferroptosis enhancement strategies remains a considerable challenge.

[0004] In response, in this study, we identified SN38, an active metabolite of a widely used chemotherapeutic drug, irinotecan, as our candidate for multimodal ferroptosis-enhanced CRC therapy. By conjugating ferrocene to SN38 via a disulfide bond, we synthesized for the first time a GSH-responsive multimodal ferroptosis-inducing molecule. First, the camptothecin derivative SN38 not only inhibits topoisomerase I, hinders tumor cell proliferation and induces apoptosis, but also regulates key proteins in ferroptosis: it downregulates nuclear transcription factor erythroid 2-related factor 2 (Nrf2), reduces GSH production and inhibits GPX4 activity, which in turn attenuates lipid peroxide decomposition and promotes ferroptosis. At the same time, SN38 upregulates p53 and enhances the expression of arachidonic acid ALOX12, thereby promoting the accumulation of lipid peroxides and promoting the ferroptosis process. This multimodal effect significantly enhances ferroptosis in colorectal cancer cells. In summary, this multimodal ferroptosis-inducing molecule depicts a novel and promising approach for the development of colorectal cancer therapy by utilizing induced ferroptosis to enhance the efficacy of chemotherapy. Summary of the invention

[0005] In view of the shortcomings of current single or dual approaches to integrate ferroptosis pathways to enhance ferroptosis in maximizing therapeutic effects, we proposed a comprehensive multimodal strategy to enhance ferroptosis by simultaneously regulating the metabolism of iron ions, amino acids, and glutathione synthesis in tumor cells, and prepared a multimodal ferroptosis-inducing molecule to significantly improve therapeutic indicators. A pragmatic approach to bring this strategy closer to clinical application is to use existing clinical drugs as the main reference for drug selection and combination therapy, that is, drug repurposing, that is, using mature drugs with known safety for new oncology uses.

[0006] The specific scheme adopted by the present invention is:

[0007] In the first aspect, the present invention seeks to protect a multimodal ferroptosis-inducing molecule, which is a ferrocene-modified SN38 prodrug, namely Fc-ss-SN38, which is obtained by chemical coupling of SN38 and ferrocene dicarboxylic acid via bis(2-hydroxyethyl) disulfide.

[0008] In a second aspect, the present invention claims a method for preparing the above-mentioned multimodal ferroptosis-inducing molecule, comprising the following steps: (1) adding bis(2-hydroxyethyl) disulfide and tert-butyldimethylsilyl chloride (TBSCl) to a DMF solution containing imidazole, and after the reaction is completed, column chromatography is performed for purification to obtain a colorless liquid compound 1; (2) Dissolve ferrocenedicarboxylic acid in DCM, add EDC and stir for 10 min, then add DMAP and compound 1. After the reaction is completed, column chromatography is performed to obtain compound 2 as a light yellow oil; (3) Add triethylamine trihydrofluoric acid to the THF solution of compound 2, stir at room temperature, and after the reaction is completed, column chromatography is performed to obtain a yellow oily compound 3; (4) adding p-nitrophenyl chloroformate to a DCM solution of compound 3 containing DIPEA, and after completion of the reaction at room temperature, column chromatography was performed to obtain compound 4; (5) SN38 was added to a DCM solution of compound 4 containing DIPEA. After the reaction was completed at room temperature, column chromatography was performed to obtain compound 5, i.e., the multimodal ferroptosis-inducing molecule.

[0009] As a further optimization of the above preparation method, in step (1), the bis(2-hydroxyethyl) disulfide is 5 mmol, the imidazole is 5 mmol, the tert-butyldimethylsilyl chloride is 11 mmol, the DMF is 5 mL, the reaction time is 24 h, and the reaction temperature is room temperature.

[0010] As a further optimization of the above preparation method, in step (2), the ferrocene dicarboxylic acid is 1.06 mmol, EDC is 2.54 mmol, DMAP is 1 mmol, compound 1 is 2.54 mmol, DCM is 10 mL, the reaction time is 24 h, and the reaction temperature is room temperature.

[0011] As a further optimization of the above preparation method, in step (3), the compound 2 is 0.85 mmol, triethylamine trihydrofluoric acid is 0.85 mmol, THF is 5 mL, the reaction time is 1 h, and the reaction temperature is room temperature.

[0012] As a further optimization of the above preparation method, in step (4), compound 3 is 0.21 mmol, p-nitrophenyl chloroformate is 0.46 mmol, DIEA is 0.69 mmol, DCM is 10 mL, the reaction time is 12 h, and the reaction temperature is room temperature.

[0013] As a further optimization of the above preparation method, in step (5), compound 4 is 0.17 mmol, SN38 is 0.42 mmol, DIEA is 1.06 mmol, DCM is 10 mL, the reaction time is 72 h, and the reaction temperature is reflux.

[0014] As a further optimization of the above preparation method, compound SN38 in the multimodal ferroptosis-inducing molecule is replaced by a chemical drug, immune adjuvant, vitamin, polyunsaturated fatty acid or sulfonamide modified with ferrocene dicarboxylic acid.

[0015] As a further optimization of the above preparation method, the chemical drug is paclitaxel or doxorubicin, the immune adjuvant is R848 or imiquimod, the vitamin is all-trans retinoic acid or vitamin E, the polyunsaturated fatty acid is arachidonic acid, and the sulfonamide drug is sulfasalazine.

[0016] In a third aspect, the present invention seeks to protect the use of the above-mentioned multi-mode ferroptosis-inducing molecule in any of the following: (1) Multimodal induction of ferroptosis in colorectal cancer cells; (2) Preparation of drugs for the treatment of colorectal cancer.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] (1) A multimodal ferroptosis-inducing molecule that can simultaneously regulate the metabolism of iron ions and glutathione synthesis in tumor cells to enhance ferroptosis and significantly improve therapeutic indicators.

[0019] (2) The prodrug of this multimodal ferroptosis-inducing molecule is an active metabolite of the clinical drug irinotecan in vivo, has a known safety profile, and can be used for new oncology purposes through drug reutilization strategies. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The carbon spectrum and hydrogen spectrum of Fc-ss-SN38 provided in Example 1.

[0021] Figure 2 This is a statistical graph showing the cytotoxicity of Fc-ss-SN38 to CT26 cells provided in Application Example 1.

[0022] Figure 3This is a statistical graph of Annexin V-FITC / PI double staining of CT26 cells by Fc-ss-SN38 provided in Application Example 1 and subsequent flow cytometry analysis.

[0023] Figure 4 This is the result of the cell scratch experiment of Fc-ss-SN38 on CT26 cells provided in Application Example 1.

[0024] Figure 5 This is the analysis result diagram of the effect of Fc-ss-SN38 on the MDA content of CT26 cells provided in Application Example 1.

[0025] Figure 6 This is the analysis result diagram of the effect of Fc-ss-SN38 on the Fe(II) content of CT26 cells provided in Application Example 1.

[0026] Figure 7 This is the analysis result diagram of the effect of Fc-ss-SN38 on the GSH content of CT26 cells provided in Application Example 1.

[0027] Figure 8 This is the in vivo anti-tumor effect result diagram of Fc-ss-SN38 on CT26 subcutaneous tumor-bearing mice provided in Application Example 2.

[0028] Fig. 9 This is a graph showing the results of an analysis of the effect of Fc-ss-SN38 on Ki-67 expression in CT26 subcutaneous tumor-bearing mice in Application Example 2.

[0029] Fig.10 This is a graph showing the results of an analysis of the effect of Fc-ss-SN38 on in vivo tumor Tunel expression in CT26 subcutaneous tumor-bearing mice provided in Application Example 2.

[0030] Fig.11 This is a graph showing the results of an analysis of the effect of Fc-ss-SN38 provided in Application Example 2 on the in vivo tumor GPX4 protein expression in CT26 subcutaneous tumor-bearing mice.

[0031] Fig.12 This is a graph showing the results of an analysis of the effect of Fc-ss-SN38 on in vivo tumor Nrf2 protein expression in CT26 subcutaneous tumor-bearing mice provided in Application Example 2.

[0032] Fig.13 This is a graph showing the in vivo anti-tumor effect of Fc-ss-SN38 on CT26 colon orthotopic tumor-bearing mice provided in Application Example 2.

[0033] Fig.14 This is a graph showing the results of an analysis of the effect of Fc-ss-SN38 on Ki-67 expression in vivo in CT26 colon orthotopic tumor-bearing mice provided in Application Example 2.

[0034] Fig.15 This is a graph showing the results of an analysis of the effect of Fc-ss-SN38 on in vivo tumor Tunel expression in CT26 colon orthotopic tumor-bearing mice provided in Application Example 2.

[0035] Fig.16 This is a graph showing the results of an analysis of the effect of Fc-ss-SN38 provided in Application Example 2 on the in vivo tumor GPX4 protein expression in CT26 colon orthotopic tumor-bearing mice.

[0036] Fig.17 This is a graph showing the results of an analysis of the effect of Fc-ss-SN38 on in vivo tumor Nrf2 protein expression in CT26 colon orthotopic tumor-bearing mice provided in Application Example 2.

[0037] Fig.18 This is the synthetic route of Fc-ss-SN38. DETAILED DESCRIPTION

[0038] The present invention provides a synthesis and preparation method of a multi-mode ferroptosis-inducing molecule. The raw materials for preparing the multi-mode ferroptosis-inducing molecule include: SN38, bis(2-hydroxyethyl) disulfide, ferrocene dicarboxylic acid and solvents (DCM, DMF and THF).

[0039] The present invention uses bis(2-hydroxyethyl) disulfide to chemically couple SN38 with ferrocene dicarboxylic acid to prepare a multi-mode ferroptosis-inducing molecule. The preparation process is simple. The multi-mode ferroptosis-inducing molecule prepared by this method has stable properties, clear structure, and acceptable yield. The effectiveness of the prepared multi-mode ferroptosis-inducing molecule is further determined, and it has good application potential in the treatment of colorectal cancer, and has a certain guiding role in the subsequent development and preparation of multi-mode ferroptosis-inducing molecules and their use in optimizing the treatment of colorectal cancer.

[0040] The synthetic route of Fc-ss-SN38 is as follows Fig.18 shown.

[0041] The multi-mode ferroptosis inducing molecule is prepared by connecting SN38 and ferrocene via bis(2-hydroxyethyl) disulfide.

[0042] The preparation method of the present invention is simple and easy to operate, and the prepared multimodal ferroptosis-inducing molecules have stable properties. At the same time, the drug molecules can be expanded to include chemical drugs such as paclitaxel and doxorubicin, immune adjuvants such as R848 and imiquimod, vitamins such as all-trans retinoic acid and vitamin E, polyunsaturated fatty acids such as arachidonic acid, and sulfonamide drugs such as sulfasalazine. It has universal applicability and is helpful to develop a series of new corresponding drug molecules with application prospects.

[0043] (1) adding bis(2-hydroxyethyl) disulfide and tert-butyldimethylsilyl chloride (TBSCl) to a DMF solution containing imidazole, and after the reaction is completed, column chromatography is performed for purification to obtain a colorless liquid compound 1;

[0044] (2) Dissolve ferrocenedicarboxylic acid in DCM, add EDC and stir for 10 min, then add DMAP and compound 1. After the reaction is completed, column chromatography is performed to obtain compound 2 as a light yellow oil;

[0045] (3) Add triethylamine trihydrofluoric acid to the THF solution of compound 2, stir at room temperature, and after the reaction is completed, column chromatography is performed to obtain a yellow oily compound 3;

[0046] (4) Add p-nitrophenyl chloroformate to a DCM solution of compound 3 containing DIPEA, and after completion of the reaction at room temperature, column chromatography is performed to obtain compound 4;

[0047] (5) SN38 was added to a DCM solution of compound 4 containing DIPEA. After the reaction was completed at room temperature, column chromatography was performed to obtain compound 5, i.e., the multimodal ferroptosis-inducing molecule (Fc-ss-SN38) described in this project.

[0048] Preferably, in step (1), the bis(2-hydroxyethyl) disulfide is 1-10 mmol, for example, 1 mmol, 2 mmol, 4 mmol, 6 mmol, 8 mmol and 10 mmol, etc., preferably 5 mmol; tert-butyldimethylchlorosilane is 1-20 mmol, for example, 1 mmol, 2 mmol, 4 mmol, 8 mmol, 10 mmol, 11 mmol, 15 mmol and 20 mmol, etc., preferably 11 mmol; imidazole is 1-10 mmol, for example, 1 mmol, 2 mmol, 4 mmol, 6 mmol, 8 mmol and 10 mmol, etc., preferably 5 mmol; 1, 8mmol and 10mmol, etc., preferably 5mmol; DMF is 2-25mL, for example, it can be 2mL, 5mL and 10mL, etc., preferably 5mL; the reaction temperature is 4-60℃, for example, it can be 4℃, 6℃, 8℃, 10℃, 12℃, 14℃, 16℃, 18℃, 20℃, 22℃, 24℃, 26℃, 28℃, 30℃, 35℃, 40℃, 45℃, 50℃, 55℃, 60℃, etc., preferably 25℃; the reaction time is 1-24h (for example, it can be 1h, 2h, 4h, 8h, 12h, 24h, etc.), preferably 4h. Preferably, in step (2), the ferrocene dicarboxylic acid is 0.1-4 mmol, for example, it can be 0.53 mmol, 1.06 mmol, 2.12 mmol and 4 mmol, etc., preferably 1.06 mmol; compound 1 is 2.4-9.6 mmol, for example, it can be 1.27 mmol, 2.54 mmol, 5.14 mmol and 9.6 mmol, etc., preferably 2.54 mmol; EDC is 2.4-9.6 mmol, for example, it can be 1.27 mmol, 2.54 mmol, 5.14 mmol and 9.6 mmol, etc., preferably 2.54 mmol; DMAP is 0.1-4 mmol , for example, it can be 0.5mmol, 1mmol, 2mmol and 4mmol, preferably 1mmol; DCM is 2-25mL, for example, it can be 2mL, 5mL and 10mL, etc., preferably 5mL; the reaction temperature is 4-60℃, for example, it can be 4℃, 6℃, 8℃, 10℃, 12℃, 14℃, 16℃, 18℃, 20℃, 22℃, 24℃, 26℃, 28℃, 30℃, 35℃, 40℃, 45℃, 50℃, 55℃, 60℃, etc., preferably 25℃; the reaction time is 12-72h (for example, it can be 12h, 24h, 36h, 48h, 60h, 72h, etc.), preferably 24h.

[0049] Preferably, in step (3), the compound 2 is 0.1-10 mmol, for example, 0.11 mmol, 0.22 mmol, 0.44 mmol, 0.88 mmol, 1.76 mmol, 3.52 mmol and 7.04 mmol, etc., preferably 0.22 mmol; triethylamine trifluoroacetate is 0.4-40 mmol, for example, 0.44 mmol, 0.88 mmol, 1.76 mmol, 3.52 mmol, 7.04 mmol, 14.08 mmol and 28.16 mmol, etc., Preferably it is 0.88mmol; THF is 2-25mL, for example, it can be 2mL, 5mL and 10mL, etc., preferably 5mL; the reaction temperature is 4-60℃, for example, it can be 4℃, 6℃, 8℃, 10℃, 12℃, 14℃, 16℃, 18℃, 20℃, 22℃, 24℃, 26℃, 28℃, 30℃, 35℃, 40℃, 45℃, 50℃, 55℃, 60℃, etc., preferably 25℃; the reaction time is 0.5-8h (for example, it can be 0.5h, 1h, 2h, 4h, 6h, 8h, etc.), preferably 1h.

[0050] Preferably, in step (4), p-nitrophenyl chloroformate is 0.1-10 mmol, for example, it can be 0.11 mmol, 0.23 mmol, 0.46 mmol, 0.92 mmol, 1.84 mmol, 3.68 mmol and 7.36 mmol, etc., preferably 0.46 mmol; compound 3 is 0.1-5 mmol, for example, it can be 0.1 mmol, 0.2 mmol, 0.4 mmol, 0.8 mmol, 1.6 mmol, 3.2 mmol and 6.4 mmol, preferably 0.21 mmol; DIEA is 0.1-15 mmol, for example, it can be 0.2 mmol, 0.4 mmol, 0.8 mmol, 1.6mmol, 3.2mmol, 6.4mmol and 12.8mmol, preferably 0.69mmol; DCM is 2-25mL, for example, it can be 2mL, 5mL, 10mL and 20mL, etc., preferably 10mL; the reaction temperature is 4-60℃, for example, it can be 4℃, 6℃, 8℃, 10℃, 12℃, 14℃, 16℃, 18℃, 20℃, 22℃, 24℃, 26℃, 28℃, 30℃, 35℃, 40℃, 45℃, 50℃, 55℃, 60℃, etc., preferably 25℃; the reaction time is 4-24h (for example, it can be 4h, 6h, 8h, 12h and 24h, etc.), preferably 12h.

[0051] Preferably, in step (5), SN38 is 0.1-5 mmol, for example, it can be 0.1 mmol, 0.2 mmol, 0.4 mmol, 0.8 mmol, 1.6 mmol, 3.2 mmol and 6.4 mmol, preferably 0.42 mmol; compound 4 is 0.05-5 mmol, for example, it can be 0.05 mmol, 0.1 mmol, 0.2 mmol, 0.4 mmol, 0.8 mmol, 1.6 mmol and 3.2 mmol, preferably 0.21 mmol; DIPEA is 0.3-15 mmol, for example, it can be 0.3 mmol, 0.6 mmol, 1.2 mmol, The reaction mixture is preferably 2.4mmol, 4.8mmol, 6.4mmol and 12.8mmol, preferably 1.26mmol; DCM is 5-25mL, for example, it can be 5mL, 10mL and 20mL, etc., preferably 10mL; the reaction temperature is 4-60℃, for example, it can be 4℃, 6℃, 8℃, 10℃, 12℃, 14℃, 16℃, 18℃, 20℃, 22℃, 24℃, 26℃, 28℃, 30℃, 35℃, 40℃, 45℃, 50℃, 55℃, 60℃, etc., preferably 25℃; the reaction time is 24-72h (for example, it can be 24h, 36h, 48h, 60h and 72h, etc.), preferably 72h.

[0052] The present invention also provides a use of the multi-mode ferroptosis-inducing molecule as described above in the treatment of colorectal cancer.

[0053] The specific application steps of the multi-mode ferroptosis inducing molecule in the treatment of colorectal cancer are:

[0054] (A) Multimodal ferroptosis-inducing molecules were added to the culture system of colorectal cancer cells and incubated for 24 hours. Cytotoxicity assay, scratch assay, flow cytometry apoptosis assay, and ferroptosis-related indicators (malondialdehyde, glutathione, and iron ion content) were then tested.

[0055] (B) The multimodal ferroptosis-inducing molecules were administered to tumor-bearing mice via tail vein injection for in vivo anti-colorectal cancer and drug safety evaluation.

[0056] Preferably, in step (A), the amount of the multimodal ferroptosis-inducing molecule added to the culture system of colorectal cancer cells is 0.03%-10% of the total culture system liquid, which is 1:(50-200), for example, it can be 0.03%, 0.06%, 0.12%, 0.25%, 0.5%, 1%, 5%, 10%, etc.

[0057] Preferably, in step (A), the cell culture temperature is 25° C., and the cell culture time is 24 hours.

[0058] Preferably, in step (B), the dosage for the tumor-bearing mice is 100 μL.

[0059] Preferably, in step (B), the tumor-bearing mice are of Balb / c breed and female gender, and the tumor-bearing modes are subcutaneous tumor-bearing and cecal in situ tumor-bearing.

[0060] In the present invention, the multimodal ferroptosis-inducing molecule has achieved excellent anti-tumor effects in the treatment of colorectal cancer, and enhances the death of colorectal cancer cells by promoting cancer cell ferroptosis in a multimodal manner.

[0061] The technical solution of the present invention is further described below with reference to the accompanying drawings and through specific implementations. It should be understood by those skilled in the art that the specific implementations are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0062] The sources of the components in the following examples are as follows: SN38 (purity 98%, Sigma), DIPEA (purity 98%, Sigma), ferrocene dicarboxylic acid (purity 98%, Sigma), bis(2-hydroxyethyl) disulfide, DCM (analytical grade, Sigma), DSPE-PEG 2k (purity 98%, Sigma), tert-butyldimethylsilyl chloride (purity 98%, Sigma), imidazole (purity 98%, Sigma), DMF (analytical grade, Sigma), EDC (purity 98%, Sigma), DMAP (purity 98%, Sigma), triethylamine trihydrofluoride (purity 98%, Sigma), THF (analytical grade, Sigma), p-nitrophenyl chloroformate (purity 98%, Sigma), DIEA (purity 98%, Sigma).

[0063] Example 1

[0064] This embodiment provides a multimodal ferroptosis-inducing molecule (Fc-ss-SN38), which is prepared by the following preparation method:

[0065] (1) Weigh 5 mg of Fc-ss-SN38 into a 2 mL plastic centrifuge tube, add 1 mL of tetrahydrofuran, and shake for 5 min to promote sample dissolution. If there is any undissolved part, sonicate for 3 min to completely dissolve it to avoid the presence of insoluble matter. Prepare a 5 mg / mL stock solution.

[0066] (2) Take 80 μL of Fc-ss-SN38 mother solution into a 5 mL plastic centrifuge tube, add 4 mL of deionized water and shake for 3 min, stir at room temperature overnight to obtain the multi-mode ferroptosis-inducing molecule working solution.

[0067] in, Figure 1 The carbon and hydrogen spectra of Fc-ss-SN38 provided in Example 1 are as follows: Figure 1 It can be seen that the multimodal ferroptosis-inducing molecules are spherical particles with uniform particle size.

[0068] Application Example 1

[0069] We performed MTT assay to investigate the cytotoxicity of Fc-ss-SN38 on CT26 cells. Figure 2 ). The results showed that Fc-ss-SN38 exhibited superior cytotoxicity. In addition, Figure 3 Annexin V-FITC / PI double staining and subsequent flow cytometry analysis showed that the apoptosis induction rate of the Fc-ss-SN38-treated group was 40%, indicating that Fc-ss-SN38 was able to significantly enhance tumor cell death. Then, in order to observe the ability of Fc-ss-SN38 to inhibit the proliferation of CT26 cells, a cell scratch assay was performed. Figure 4 As shown, the cell migration rate of the Fc-ss-SN38-treated group at 24h and 48h was lower than that of the control group, indicating that Fc-ss-SN38 exhibited significant anti-tumor cell proliferation ability. The above results show that Fc-ss-SN38 has a significant effect of inducing apoptosis and inhibiting cancer cell proliferation, indicating that Fc-ss-SN38 has superior anti-tumor potential in vitro.

[0070] Based on the significant anti-tumor effect of Fc-ss-SN38 in vitro, the ferroptosis-related molecular mechanism of Fc-ss-SN38-induced cell death in CT26 cells was further explored. The exploration projects mainly include intracellular oxidative stress markers MDA ( Figure 5 ), ferrous ions ( Figure 6 ) and GSH( Figure 7 ) content. The MDA content in the Fc-ss-SN38-treated group was 16 times that in the control group; the Fe(II) and total iron content in the Fc-ss-SN38-treated group were higher than those in the control group, proving that Fc-ss-SN38 significantly caused iron overload in CT26 cells; the cysteine ​​and GSH content in the Fc-ss-SN38-treated group were lower than those in the control group. These results indicate that Fc-ss-SN38 can cascade reduce the production of GSH.

[0071] Application Example 2

[0072] To verify the antitumor effect of Fc-ss-SN38 in the subcutaneous CT26 tumor model, Fc-ss-SN38 was injected intravenously via the tail vein, and the changes in tumor volume were monitored. Figure 8As shown, the tumor volume increased the least in the Fc-ss-SN38-treated group, indicating that the use of Fc-ss-SN38 had a significant inhibitory effect on tumor growth. After the treatment was completed, the mice were humanely killed and the tumors were removed for observation and measurement. Compared with the control group, the average tumor weight in the Fc-ss-SN38-treated group was the smallest, and the use of Fc-ss-SN38 once again showed an excellent in vivo anti-tumor effect. In order to observe the internal conditions of the tumor more microscopically, sections were prepared from the tumor tissue, as shown in Figure 2. Fig. 9 and Fig.10 As shown, the results of Ki67 and TUNEL showed that the Fc-ss-SN38-treated group had the least Ki-67 positive cells, while the TUNEL positive cells were more than those in the other groups. The above results indicate that Fc-ss-SN38 triggers necrosis and apoptosis and exerts an inhibitory effect, indicating its anti-tumor properties.

[0073] Based on the ability of Fc-ss-SN38 to trigger ferroptosis in monolayers of CT26 cells, the biological mechanisms of ferroptosis in animal models were further investigated by evaluating specific markers in subcutaneous CT26 tumor-bearing mice. Fig.11 The fluorescence signal of GPX4 in the Fc-ss-SN38-treated group was weaker than that in the control group, indicating that the Fc-ss-SN38-treated group had the most severe reduction in the ability to clear cellular lipid peroxides in vivo compared with the control group. In addition, the fluorescence signal of Nrf2 in Fc-ss-SN38 was the weakest compared with the control group, further indicating that Fc-ss-SN38 caused the downregulation of Nrf2 in vivo ( Fig.12 These results indicate that Fc-ss-SN38 inhibits tumor growth through robust ferroptosis in tumors, suggesting that Fc-ss-SN38 promotes tumor cell death and achieves antitumor effects through a multimodal cascade of ferroptosis in a subcutaneous CT26 tumor-bearing mouse model.

[0074] Application Example 3

[0075] In order to more objectively simulate the entire process of tumor occurrence, development, and invasion in vivo, an orthotopic mouse colon cancer tumor model was constructed to more objectively evaluate the anti-tumor effect of Fc-ss-SN38.

[0076] like Fig.13 As shown in the figure, after the treatment was completed, the mice were humanely killed and the tumors were removed for observation and measurement. Compared with the control group, the average tumor weight of the Fc-ss-SN38-treated group was smaller, and the use of Fc-ss-SN38 once again demonstrated an in vivo anti-tumor effect. Fig.14 and Fig.15 As shown in Figure 2, the results of Ki67 and TUNEL showed that the Fc-ss-SN38-treated group had fewer Ki-67-positive cells and more TUNEL-positive cells than the control group. Fig.16As shown in the figure, the fluorescence signal of GPX4 in the tumor of the Fc-ss-SN38-treated group was weaker than that of the control group, revealing that the lipid peroxide scavenging ability of the cells in the Fc-ss-SN38-treated group was most seriously decreased compared with the control group. Secondly, compared with the control group, the fluorescence signal of Nrf2 in Fc-ss-SN38 was weak, further indicating that Fc-ss-SN38 caused Nrf2 downregulation in the orthotopic CT26 tumor-bearing mouse model ( Fig.17 ).

[0077] The above results further illustrate the objective fact that Fc-ss-SN38 exerts its powerful anti-tumor effect through the cascade amplification of ferroptosis effects in the actual process of tumor growth, development and invasion in the orthotopic model.

[0078] The applicant declares that the present invention illustrates the multi-mode ferroptosis-inducing molecule and its preparation method and application through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, the equivalent replacement of the raw materials of the product of the present invention, the addition of auxiliary components, the selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A multimodal ferroptosis-inducing molecule, characterized in that: The multimodal ferroptosis inducing molecule is a ferrocene-modified SN38 prodrug, namely Fc-ss-SN38, which is obtained by chemical coupling of SN38 and ferrocene dicarboxylic acid via bis(2-hydroxyethyl) disulfide.

2. The method for preparing a multimodal ferroptosis-inducing molecule according to claim 1, characterized in that: The following steps are involved: (1) adding bis(2-hydroxyethyl) disulfide and tert-butyldimethylsilyl chloride (TBSCl) to a DMF solution containing imidazole, and after the reaction is completed, column chromatography is performed for purification to obtain a colorless liquid compound 1; (2) Dissolve ferrocenedicarboxylic acid in DCM, add EDC and stir for 10 min, then add DMAP and compound 1. After the reaction is completed, column chromatography is performed to obtain compound 2 as a light yellow oil; (3) Add triethylamine trihydrofluoric acid to the THF solution of compound 2, stir at room temperature, and after the reaction is completed, column chromatography is performed to obtain a yellow oily compound 3; (4) adding p-nitrophenyl chloroformate to a DCM solution of compound 3 containing DIPEA, and after completion of the reaction at room temperature, column chromatography was performed to obtain compound 4; (5) SN38 was added to a DCM solution of compound 4 containing DIPEA. After the reaction was completed at room temperature, column chromatography was performed to obtain compound 5, i.e., the multimodal ferroptosis-inducing molecule.

3. The preparation method according to claim 2, characterized in that: In step (1), the bis(2-hydroxyethyl) disulfide is 5 mmol, imidazole is 5 mmol, tert-butyldimethylsilyl chloride is 11 mmol, DMF is 5 mL, the reaction time is 24 h, and the reaction temperature is room temperature.

4. The preparation method according to claim 2, characterized in that: In step (2), the ferrocene dicarboxylic acid is 1.06 mmol, EDC is 2.54 mmol, DMAP is 1 mmol, compound 1 is 2.54 mmol, DCM is 10 mL, the reaction time is 24 h, and the reaction temperature is room temperature.

5. The preparation method according to claim 2, characterized in that: In step (3), the compound 2 is 0.85 mmol, triethylamine trihydrofluoric acid is 0.85 mmol, THF is 5 mL, the reaction time is 1 h, and the reaction temperature is room temperature.

6. The preparation method according to claim 2, characterized in that: In step (4), the amount of compound 3 was 0.21 mmol, the amount of p-nitrophenyl chloroformate was 0.46 mmol, the amount of DIEA was 0.69 mmol, the amount of DCM was 10 mL, the reaction time was 12 h, and the reaction temperature was room temperature.

7. The preparation method according to claim 2, characterized in that: In step (5), compound 4 is 0.17 mmol, SN38 is 0.42 mmol, DIEA is 1.06 mmol, DCM is 10 mL, the reaction time is 72 h, and the reaction temperature is reflux.

8. The preparation method according to claim 2, characterized in that: The compound SN38 in the multimodal ferroptosis-inducing molecule is replaced by a chemical drug, an immune adjuvant, a vitamin, a polyunsaturated fatty acid or a sulfonamide drug modified with ferrocene dicarboxylic acid.

9. The preparation method according to claim 8, characterized in that: The chemical drug is paclitaxel or doxorubicin, the immune adjuvant is R848 or imiquimod, the vitamin is all-trans retinoic acid or vitamin E, the polyunsaturated fatty acid is arachidonic acid, and the sulfonamide drug is sulfasalazine.

10. Use of the multimodal ferroptosis-inducing molecule according to claim 1 or the multimodal ferroptosis-inducing molecule prepared by the preparation method according to any one of claims 2 to 9 in any of the following: (1) Multimodal induction of ferroptosis in colorectal cancer cells; (2) Preparation of drugs for the treatment of colorectal cancer.

Citation Information

Patent Citations

  • Compound with chemical kinetics effect and preparation method of nano vesicle

    CN113416217A

  • Disulfide bond bridged SN38 dimer prodrug as well as self-assembled nanoparticles, preparation method and application of disulfide bond bridged SN38 dimer prodrug

    CN115844891A

  • Preparation and application of micromolecular self-assembled nano prodrug combined with chemotherapy and ferroptosis treatment

    CN116327774A

  • Bioactive conjugate, preparation method therefor and use thereof

    WO2019114666A1